MarketCap
Facebook
X
Telegram
BioCardia Financial Ratios 2025-2009 | BCDA
Brief overview of BioCardia's valuation and returns
The comparison uses the five latest available annual observations between 2011 and 2015.
Market valuation is represented by P/E 57.22x (median 57.22x), EV/EBITDA 14.37x (median 310.5x), P/S 57.24x (median 30.84x). The combined multiple level is about 42.8% above the company's historical norm, leaving less valuation cushion.
At the current P/E, inverse earnings yield is 1.7%, a useful bridge between price and business earnings.
Capital efficiency is characterized by ROE -9.2%, ROA -2.4%, ROCE -9.2%. Losses and negative capital returns make ordinary P/E-like references unstable or inapplicable.
PEG of 0.14x shows valuation is not outpacing embedded growth. The conclusion depends on earnings durability.
Valuation takeaway
BioCardia combines weak profitability with valuation above its historical norm, leaving limited cushion.
Annual Financial Ratios BioCardia
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.0 | -0.4 | -0.1 | -3.1 | -2.5 | -3.5 | -2.0 | -4.1 | -8.1 | -7.7 | 57.2 | 108.3 | 969.7 | 52.9 | 2.1 | -24311.9 | - |
P/S |
- | 57.2 | 1.2 | 27.4 | 30.8 | 357.7 | 40.8 | 92.7 | 207.1 | 137.7 | 35.6 | 59.3 | 68.7 | 260.0 | 1727.2 | - | - |
EPS |
-1.2 | -2.9 | -8.2 | -0.7 | -0.8 | -1.5 | -2.6 | -3.3 | -2.9 | -1.2 | -4.3 | - | - | - | 0.0 | -0.1 | - |
EV (Enterprise Value) |
8.09 M | 3.84 M | 4.08 M | 34.6 M | 23.8 M | 34.7 M | 28.7 M | 55.2 M | 88.9 M | 59.5 M | 14.9 M | 22.1 M | 5.15 M | 2.86 M | 8.8 M | 280 B | -4.97 M |
EBITDA per Share |
-1.24 | -2.89 | -8.19 | -0.67 | -0.74 | -1.23 | -2.5 | -3.29 | -2.91 | -8.14 | 0.15 | 0.108 | 0.00422 | -0.159 | -0.285 | - | - |
EV/EBITDA |
-1.0 | -0.5 | -0.4 | -2.9 | -0.7 | -2.0 | -1.7 | -3.8 | -7.0 | -7.7 | 14.4 | 51.2 | 569.8 | -8.4 | -13.3 | 728667.2 | - |
PEG |
-0.01 | -0.0 | -0.0 | 0.14 | 0.07 | -0.06 | -0.1 | 0.33 | -0.11 | 0.0 | 1.52 | 0.1 | -10.34 | -0.55 | 0.01 | - | - |
P/B |
9.0 | 4.0 | -0.4 | 7.6 | 3.0 | 2.7 | 12.2 | 15.3 | 8.9 | 3.9 | 1.3 | 1.9 | 1.4 | 1.2 | 1.6 | 85332.8 | - |
P/CF |
-1.1 | -0.4 | -0.1 | -3.5 | -3.0 | -4.2 | -3.0 | -5.2 | -11.3 | -14.4 | 55.7 | 118.4 | 682.3 | -52.0 | -6.4 | -65421.1 | - |
ROE % |
-919.33 | -949.34 | 721.83 | -243.40 | -121.67 | -78.24 | -620.63 | -368.86 | -110.63 | -50.09 | 2.32 | 1.73 | 0.14 | 2.30 | 74.45 | -350.99 | - |
ROA % |
-241.08 | -213.37 | -387.38 | -121.59 | -80.31 | -64.05 | -191.57 | -217.97 | -90.91 | -46.69 | 2.32 | 1.73 | 0.14 | 2.29 | 70.35 | -211.76 | - |
ROCE % |
-924.92 | -955.91 | 726.39 | -243.27 | -121.73 | -80.98 | -386.75 | -364.49 | -110.70 | -36.86 | 2.30 | 1.71 | 0.07 | -2.55 | -4.76 | -17.78 | - |
Current Ratio |
1.4 | 1.3 | 0.7 | 2.0 | 2.9 | 5.3 | 1.6 | 2.4 | 5.7 | 15.2 | 1387.6 | 13545.0 | 740.4 | 1108.4 | 18.2 | 2.5 | - |
DSO |
- | 198.2 | 101.0 | 47.0 | 68.1 | - | 75.6 | 160.0 | 72.4 | 46.9 | - | - | - | - | 2037.9 | - | - |
DIO |
- | - | - | - | - | - | 4.1 | 99.5 | 101.0 | 66.1 | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | 68072.5 | 931.9 | 720.1 | 477.1 | 256.9 | - | - | - | - | - | - | - |
Operating Cycle |
- | 198.2 | 101.0 | 47.0 | 68.2 | - | 79.6 | 259.6 | 173.4 | 112.9 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | 198.2 | 101.0 | 47.0 | 68.2 | -68072.5 | -852.2 | -460.6 | -303.7 | -143.9 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios BioCardia
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.13 | -0.21 | - | -0.24 | -0.4 | -0.59 | - | -0.61 | -0.88 | -1.35 | - | -1.79 | -2.52 | -0.17 | - | -0.17 | -0.14 | -0.19 | - | -0.16 | -0.2 | -0.18 | - | -0.3 | -0.46 | -0.67 | - | -0.63 | -0.77 | -0.86 | - | -0.83 | -0.76 | -0.09 | - | -0.08 | -0.08 | -0.08 | - | -2.06 | -0.11 | -0.08 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.05 | 0.05 | - |
EBITDA per Share |
-0.17 | -0.21 | - | -0.24 | -0.4 | -0.59 | - | -0.62 | -0.87 | -1.35 | - | -1.79 | -2.52 | -0.17 | - | -0.17 | -0.14 | -0.19 | - | -0.16 | -0.2 | -0.18 | - | -0.3 | -0.46 | -0.67 | - | -0.52 | -0.77 | -0.86 | - | -0.82 | -0.75 | -0.09 | - | -0.08 | -0.08 | -0.08 | - | -1.05 | -0.07 | -0.06 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-59.91 | 442.53 | 230.61 | 167.52 | 307.91 | 298.91 | 120.49 | 510.49 | 364.17 | 95.97 | -3.68 | -78.30 | -37548.78 | -37384.49 | -37200.22 | -37220.40 | -37168.03 | -103.54 | -58.42 | -78.49 | -76.94 | -78.65 | -62.66 | -222.66 | -360.82 | -496.83 | -472.87 | -566.33 | -491.17 | -427.45 | -272.81 | -299.79 | -232.80 | -173.81 | -79.30 | -95.11 | -77.74 | -58.54 | -32.69 | -32.09 | -15.75 | -5.60 | 1.67 | 1.99 | 1.88 | 1.82 | 1.27 | 1.50 | 1.25 | 0.57 | 0.10 | 3.50 | 2.30 | 1.82 | 2.01 | -2.31 | 77.79 | 76.29 | 76.70 | -4.32 | 83.50 | -2.47 |
ROA % |
-333.62 | -379.37 | -247.41 | -275.13 | -307.96 | -294.50 | -169.29 | -237.99 | -263.86 | -256.02 | -171.40 | -204.71 | -158.18 | -130.48 | -81.36 | -96.98 | -80.92 | -71.50 | -45.60 | -62.03 | -61.67 | -64.03 | -51.29 | -100.68 | -133.09 | -165.57 | -145.96 | -201.19 | -201.94 | -208.95 | -161.21 | -183.38 | -149.90 | -121.02 | -65.16 | -79.90 | -66.69 | -51.71 | -30.47 | -29.87 | -14.61 | -5.10 | 1.67 | 1.99 | 1.88 | 1.82 | 1.27 | 1.50 | 1.25 | 0.57 | 0.10 | 3.49 | 2.30 | 1.82 | 2.01 | -2.08 | 73.43 | 72.06 | 72.48 | -4.08 | 78.90 | -2.34 |
ROCE % |
19.63 | 444.02 | 231.45 | 167.66 | 308.40 | 299.65 | 120.30 | 513.94 | 366.59 | 97.77 | -2.23 | -76.92 | -37536.19 | -37370.21 | -37185.47 | -37205.67 | -37153.24 | -103.61 | -58.46 | -78.53 | -76.98 | -78.75 | -62.74 | -198.90 | -337.57 | -474.50 | -450.46 | -544.61 | -494.21 | -430.94 | -275.37 | -302.69 | -235.22 | -175.30 | -79.84 | -88.01 | -67.39 | -45.94 | -20.10 | -19.50 | -10.81 | -3.57 | 1.66 | 1.97 | 1.85 | 1.79 | 1.25 | 1.45 | 1.18 | 0.51 | 0.04 | -0.58 | -1.77 | -2.25 | -2.05 | -2.90 | -4.20 | -3.98 | -3.54 | -0.85 | -1.92 | -0.78 |
Current Ratio |
1.4 | 0.6 | 1.3 | 1.8 | 0.5 | 0.6 | 1.3 | 1.8 | 0.6 | 0.5 | 0.7 | 0.8 | 1.3 | 1.4 | 2.0 | 1.8 | 2.5 | 2.4 | 2.9 | 4.4 | 4.5 | 4.9 | 5.5 | 5.5 | 5.5 | 5.5 | 1.4 | 1.4 | 1.4 | 1.4 | 2.4 | 2.4 | 2.4 | 2.4 | 5.6 | 5.6 | 5.6 | 5.6 | 14.7 | 14.7 | 14.7 | 14.7 | 0.6 | 1387.6 | 1387.6 | 1387.6 | 1387.6 | 13545.0 | 13545.0 | - | 13545.0 | 2697.6 | 13441.0 | 13375.0 | 1108.4 | 1108.4 | 1108.4 | 1108.4 | 18.2 | 18.2 | 18.2 | 18.2 |
DSO |
- | - | - | - | - | - | - | - | 1034.2 | 100.4 | - | 28.0 | 284.4 | 252.4 | - | 110.0 | 25.1 | 359.7 | - | 23.7 | 277.1 | 418.6 | - | 622.6 | 784.1 | 455.1 | - | 69.1 | 156.0 | 88.9 | - | 297.6 | 104.6 | 84.6 | - | 66.7 | 77.4 | 56.3 | - | 57.7 | 46.9 | 46.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.3 | 128.8 | 377.4 | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 45.6 | - | 15.2 | 1.9 | 62.4 | - | 118.0 | 95.3 | 96.5 | - | 118.6 | 85.9 | 85.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18934.4 | - | 3475.1 | 436.7 | 713.2 | - | 738.0 | 689.4 | 558.5 | - | 559.9 | 405.5 | 372.0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | 1034.2 | 100.4 | - | 28.0 | 284.4 | 252.4 | - | 110.0 | 25.1 | 359.7 | - | 23.7 | 277.1 | 418.6 | - | 622.6 | 784.1 | 500.7 | - | 84.3 | 157.9 | 151.3 | - | 415.7 | 199.9 | 181.1 | - | 185.2 | 163.3 | 141.3 | - | 57.7 | 46.9 | 46.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.3 | 128.8 | 377.4 | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | 1034.2 | 100.4 | - | 28.0 | 284.4 | 252.4 | - | 110.0 | 25.1 | 359.7 | - | 23.7 | 277.1 | 418.6 | - | 622.6 | 784.1 | -18433.7 | - | -3390.8 | -278.8 | -561.9 | - | -322.3 | -489.5 | -377.5 | - | -374.7 | -242.2 | -230.8 | - | 57.7 | 46.9 | 46.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | 115.3 | 128.8 | 377.4 | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company BioCardia, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
Canada
China
Israel
France
Germany
Britain
Russia
Belgium
Cayman-islands
